Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase type 1

Journal of Medicinal Chemistry

Volumn 54, Issue 17, 2011, Pages 6050-6062

  Xu, Zhenrong ^a   Tice, Colin M ^a   Zhao, Wei ^a   Cacatian, Salvacion ^a   Ye, Yuan Jie ^a   Singh, Suresh B ^a   Lindblom, Peter ^a   McKeever, Brian M ^a   Krosky, Paula M ^a   Kruk, Barbara A ^a   Berbaum, Jennifer ^a   Harrison, Richard K ^a   Johnson, Judith A ^a   Bukhtiyarov, Yuri ^a   Panemangalore, Reshma ^a   Scott, Boyd B ^a   Zhao, Yi ^a   Bruno, Joseph G ^a   Togias, Jennifer ^a   Guo, Joan ^a   Guo, Rong ^a   Carroll, Patrick J ^b   McGeehan, Gerard M ^a   Zhuang, Linghang ^a   He, Wei ^a   Claremon, David A ^a   more..

^a Vitae Pharmaceuticals   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 3 [1 (2,4 DIFLUORO (1,1 BIPHENYL) 4 YL)ETHYL] 6 (4 FLUOROPHENYL) 6 (2 HYDROXYETHYL) 1,3 OXAZINAN 2 ONE; ANTIDIABETIC AGENT; HYDROCORTISONE; OXIDOREDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROCORTISONE BLOOD LEVEL; IC 50; IN VITRO STUDY; LIVER; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; RAT; TARGET CELL;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADIPOCYTES; ADMINISTRATION, ORAL; ANIMALS; CELLS, CULTURED; CHO CELLS; CORTISONE; CRICETINAE; CRICETULUS; ENZYME INHIBITORS; HUMANS; MACACA FASCICULARIS; MICE; OXAZINES; RATS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 80052367616     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2005354     Document Type: Article

References (45)

1. Puranen, T.; Poutanen, M.; Ghosh, D.; Vihko, P.; Vihko, R. Mol. Endocrinol. 1997, 11, 77.
2. Frye, S. V.; Haffner, C. D.; Maloney, P. R.; Mook, R. A.; Dorsey, G. F.; Hiner, R. N.; Cribbs, C. M.; Wheeler, T. N.; Ray, J. A. J. Med. Chem. 1994, 37, 2352.
3. Parks, D. J.; Blanchard, S. G.; Bledsoe, R. K.; Chandra, G.; Consler, T. G.; Kliewer, S. A.; Stimmel, J. B.; Willson, T. M.; Zavacki, A. M.; Moore, D. D.; Lehmann, J. M. Science 1999, 284, 1365.
4. Grover, G. S.; Turner, B. A.; Parker, C. N.; Meier, J.; Lala, D. S.; Lee, P. H. J. Biomol. Screening 2003, 8, 239.
5. Diabetes Atlas, 4 th ed.; IDF: Brussels, Belgium, 2009.
6. Alberti, K. G. M. M.; Eckel, R. H.; Grundy, S. M.; Zimmet, P. Z.; Cleeman, J. I.; Donato, K. A.; Fruchart, J.-C.; James, W. P. T.; Loria, C. M.; Smith, S. C., Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation 2009, 120, 1640-1645
7. Mohler, M. L.; He, Y.; Wu, Z.; Hwang, D. J.; Miller, D. D. Recent and emerging anti-diabetes targets Med. Res. Rev. 2009, 29, 125-195
8. Tanaka, N.; Nonaka, T.; Nakamura, K. T.; Hara, A. SDR: structure, mechanism of action, and substrate recognition Curr. Org. Chem. 2001, 5, 89-111 (Pubitemid 32421676)
9. Bray, J. E.; Marsden, B. D.; Oppermann, U. The human short-chain dehydrogenase/reductase (SDR) superfamily: a bioinformatics summary Chem.-Biol. Interact. 2009, 178, 99-109
10. Jacobson, L. Hypothalamic-pituitary-adrenocortical axis regulation Endocrinol. Metab. Clin. North Am. 2005, 34, 271-292 (Pubitemid 40602721)
11. Harno, E.; White, A. Will treating diabetes with 11beta-HSD1 inhibitors affect the HPA axis? Trends Endocrinol. Metab. 2010, 21, 619-627
12. Albiston, A. L.; Obeyesekere, V. R.; Smith, R. E.; Krozowski, Z. S. Cloning and tissue distribution of the human 11beta-hydroxysteroid dehydrogenase type 2 enzyme Mol. Cell. Endocrinol. 1994, 105, R11-R17
13. Cooper, M. S.; Stewart, P. M. 11beta-Hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation J. Clin. Endocrinol. Metab. 2009, 94, 4645-4654
14. Wamil, M.; Seckl, J. R. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target Drug Discovery Today 2007, 12, 504-520 (Pubitemid 47031664)
15. Fotsch, C.; Wang, M. Blockade of glucocorticoid excess at the tissue level: inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 as a therapy for type 2 diabetes J. Med. Chem. 2008, 51, 4851-4857
16. Saiah, E. The role of 11beta-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11beta-HSD1 inhibitors Curr. Med. Chem. 2008, 15, 642-649 (Pubitemid 351516801)
17. Walker, B. R.; Andrew, R. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease Ann. N.Y. Acad. Sci. 2006, 1083, 165-184 (Pubitemid 44955472)
18. Tomlinson, J. W.; Stewart, P. M. Modulation of glucocorticoid action and the treatment of type-2 diabetes Best Pract. Res., Clin. Endocrinol. Metab. 2007, 21, 607-619 (Pubitemid 350177564)
19. Bertagna, X.; Guignat, L.; Groussin, L.; Bertherat, J. Cushing's disease Best Pract. Res., Clin. Endocrinol. Metab. 2009, 23, 607-623
20. Masuzaki, H.; Paterson, J.; Shinyama, H.; Morton, N. M.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. A transgenic model of visceral obesity and the metabolic syndrome Science (Washington, DC, U. S.) 2001, 294, 2166-2170 (Pubitemid 33150673)
21. Masuzaki, H.; Yamamoto, H.; Kenyon, C. J.; Elmquist, J. K.; Morton, N. M.; Paterson, J. M.; Shinyama, H.; Sharp, M. G. F.; Fleming, S.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice J. Clin. Invest. 2003, 112, 83-90 (Pubitemid 38056379)
22. Kotelevitsev, Y.; Holmes, M. C.; Burchell, A.; Houston, P. M.; Schmoll, D.; Jamieson, P.; Best, R.; Brown, R.; Edwards, C. R. W.; Seckl, J. R.; Mullins, J. J. 11beta-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 14924-14929 (Pubitemid 28041476)
23. Morton, N. M.; Paterson, J. M.; Masuzaki, H.; Holmes, M. C.; Staels, B.; Fievet, C.; Walker, B. R.; Flier, J. S.; Mullins, J. J.; Seckl, J. R. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11beta-hydroxysteroid dehydrogenase type 1-deficient mice Diabetes 2004, 53, 931-938 (Pubitemid 38436604)
24. Morton, N. M.; Holmes, M. C.; Fievet, C.; Staels, B.; Tailleux, A.; Mullins, J. J.; Seckl, J. R. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice J. Biol. Chem. 2001, 276, 41293-41300
25. Andrews, R. C.; Rooyackers, O.; Walker, B. R. Effects of the 11beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes J. Clin. Endocrinol. Metab. 2003, 88, 285-291 (Pubitemid 36115179)
26. Sandeep, T. C.; Andrew, R.; Homer, N. Z. M.; Andrews, R. C.; Smith, K.; Walker, B. R. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone Diabetes 2005, 54, 872-879 (Pubitemid 40322093)
27. Barf, T.; Vallgårda, J.; Emond, R.; Haeggstroem, C.; Kurz, G.; Nygren, A.; Larwood, V.; Mosialou, E.; Axelsson, K.; Olsson, R.; Engblom, L.; Edling, N.; Roenquist-Nii, Y.; Oehman, B.; Alberts, P.; Abrahmsen, L. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 J. Med. Chem. 2002, 45, 3813-3815 (Pubitemid 35024284)
28. St. Jean, D. J., Jr.; Wang, M.; Fotsch, C. Inhibitors of 11beta-HSD1: a potential treatment for the metabolic syndrome Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2008, 8, 1508-1523
29. Boyle, C. D. Recent advances in the discovery of 11beta-HSD1 inhibitors Curr. Opin. Drug Discovery Dev. 2008, 11, 495-511 (Pubitemid 351950845)
30. Schnackenberg, C. G. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome Curr. Opin. Invest. Drugs (Thomson Sci.) 2008, 9, 295-300 (Pubitemid 351323383)
31. Hermanowski-Vosatka, A.; Balkovec, J. M.; Cheng, K.; Chen, H. Y.; Hernandez, M.; Koo, G. C.; Le Grand, C. B.; Li, Z.; Metzger, J. M.; Mundt, S. S.; Noonan, H.; Nunes, C. N.; Olson, S. H.; Pikounis, B.; Ren, N.; Robertson, N.; Schaeffer, J. M.; Shah, K.; Springer, M. S.; Strack, A. M.; Strowski, M.; Wu, K.; Wu, T.; Xiao, J.; Zhang, B. B.; Wright, S. D.; Thieringer, R. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice J. Exp. Med. 2005, 202, 517-527 (Pubitemid 41186950)
32. Veniant, M. M.; Hale, C.; Hungate, R. W.; Gahm, K.; Emery, M. G.; Jona, J.; Joseph, S.; Adams, J.; Hague, A.; Moniz, G.; Zhang, J.; Bartberger, M. D.; Li, V.; Syed, R.; Jordan, S.; Komorowski, R.; Chen, M. M.; Cupples, R.; Kim, K. W.; St. Jean, D. J.; Johansson, L.; Henriksson, M. A.; Williams, M.; Vallgarda, J.; Fotsch, C.; Wang, M. Discovery of a potent, orally active 11.beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1 S,2 S,4 R)-bicyclo[2.2.1]heptan-2-ylamino)-5- isopropyl-5-methylthiazol-4(5 H)-one (AMG 221) J. Med. Chem. 2010, 53, 4481-4487
33. Sundbom, M.; Kaiser, C.; Bjoerkstrand, E.; Castro, V. M.; Larsson, C.; Selen, G.; Nyhem, C. S.; James, S. R. Inhibition of 11beta HSD1 with the S -phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice BMC Pharmacol. 2008, 8, 3
34. Hale, C.; Veniant, M.; Wang, Z.; Chen, M.; McCormick, J.; Cupples, R.; Hickman, D.; Min, X.; Sudom, A.; Xu, H.; Matsumoto, G.; Fotsch, C.; St. Jean, D. J., Jr.; Wang, M. Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor Chem. Biol. Drug Des. 2008, 71, 36-44
35. Wan, Z.-K.; Chenail, E.; Xiang, J.; Li, H.-Q.; Ipek, M.; Bard, J.; Svenson, K.; Mansour, T. S.; Xu, X.; Tian, X.; Suri, V.; Hahm, S.; Xing, Y.; Johnson, C. E.; Li, X.; Qadri, A.; Panza, D.; Perreault, M.; Tobin, J. F.; Saiah, E. Efficacious 11β-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model J. Med. Chem. 2009, 52, 5449-5461
36. Whittamore, P. R. O. Discovery of a Potent, Selective and Orally Bioavailable Acidic 11beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitor. Presented at EFMC-ISMC 2010, Brussels, Belgium, 2010.
37. Rosenstock, J.; Banarer, S.; Fonseca, V. A.; Inzucchi, S. E.; Sun, W.; Yao, W.; Hollis, G.; Flores, R.; Levy, R.; Williams, W. V.; Seckl, J. R.; Huber, R. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy Diabetes Care 2010, 33, 1516-1522
38. Feig, P. U.; Shah, S.; Hermanowski-Vosatka, A.; Plotkin, D.; Springer, M. S.; Donahue, S.; Thach, C.; Klein, E. J.; Lai, E.; Kaufman, K. D. Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome Diabetes, Obes. Metab. 2011, 13, 498-504
39. Zhang, J.; Osslund, T. D.; Plant, M. H.; Clogston, C. L.; Nybo, R. E.; Xiong, F.; Delaney, J. M.; Jordan, S. R. Crystal structure of murine 11beta-hydroxysteroid dehydrogenase 1: an important therapeutic target for diabetes Biochemistry 2005, 44, 6948-6957 (Pubitemid 40632413)
40. Patel, J. R.; Shuai, Q.; Dinges, J.; Winn, M.; Pliushchev, M.; Fung, S.; Monzon, K.; Chiou, W.; Wang, J.; Pan, L.; Wagaw, S.; Engstrom, K.; Kerdesky, F. A.; Longenecker, K.; Judge, R.; Qin, W.; Imade, H. M.; Stolarik, D.; Beno, D. W. A.; Brune, M.; Chovan, L. E.; Sham, H. L.; Jacobson, P.; Link, J. T. Discovery of adamantane ethers as inhibitors of 11beta-HSD-1: synthesis and biological evaluation Bioorg. Med. Chem. Lett. 2007, 17, 750-755 (Pubitemid 46108559)
41. Andersson, A.; Jordan, D.; Schneider, G.; Lindqvist, Y. Crystal structure of the ternary complex of 1,3,8-trihydroxynaphthalene reductase from Magnaporthe grisea with NADPH and an active-site inhibitor Structure (London) 1996, 4, 1161-1170 (Pubitemid 27005384)
42. "Contour" is a structure-based drug design tool that grows molecules in silico, in the context of a protein binding site, by addition of fragments to a user selected starting template: Singh, S. B. Manuscript in preparation.
43. Solly, K.; Mundt, S. S.; Zokian, H. J.; Ding, G. J.-F.; Hermanowski-Vosatka, A.; Strulovici, B.; Zheng, W. High-throughput screening of 11beta-hydroxysteroid dehydrogenase type 1 in scintillation proximity assay format Assay Drug Dev. Technol. 2005, 3, 377-384 (Pubitemid 41489393)
44. Nagao, M.; Yahagi, T.; Honda, M.; Seino, Y.; Matsushima, T.; Sugimura, T. Demonstration of mutagenicity of aniline and o -toluidine by norharman Proc. Jpn. Acad., Ser. B 1977, 53, 34-37
45. Hecht, S. S.; El-Bayoumy, K.; Tulley, L.; LaVoie, E. Structure- mutagenicity relationships of N-oxidized derivatives of aniline, o -toluidine, 2′-methyl-4-aminobiphenyl, and 3,2′-dimethyl-4-aminobiphenyl J. Med. Chem. 1979, 22, 981-987 (Pubitemid 10235937)